Table 5.
Risk of hepatocellular carcinoma (HCC) according to HCC risk scores
| No. with HCC/at risk (overall) | Cumulative HCC incidence rate (%) at 5 yr (overall) | No. with HCC/at risk (spontaneous) | Cumulative HCC incidence rate (%) at 5 yr (spontaneous) | No. with HCC/at risk (AVT-induced) | Cumulative HCC incidence rate (%) at 5 yr (AVT-induced) | |
| CU-HCC | ||||||
| Low (<5) | 9/1,026 | 0.6 | 7/869 | 0.5 | 2/157 | 1.3 |
| Medium (5–19) | 12/158 | 5.3 | 3/101 | 2.0 | 9/57 | 10.7 |
| High (≥20) | 2/16 | 14.3 | 2/14 | 16.7 | 0/2 | |
| GAG-HCC | ||||||
| Low (<100) | 12/1,093 | 0.8 | 7/905 | 0.5 | 5/188 | 2.3 |
| High (≥100) | 11/107 | 7.9 | 5/79 | 5.6 | 6/28 | 14.3 |
| REACH-B | ||||||
| Low (<8) | 8/705 | 0.1 | 5/555 | 0.8 | 3/150 | 1.7 |
| High (≥8) | 15/495 | 0.2 | 7/429 | 0.9 | 8/66 | 8.6 |
| PAGE-B | ||||||
| Low (≤9) | 0/171 | 0.0 | 0/146 | 0.0 | 0/25 | 0.0 |
| Intermediate (10–17) | 12/616 | 1.3 | 6/500 | 0.8 | 6/116 | 3.4 |
| High (≥18) | 11/413 | 2.1 | 6/338 | 1.3 | 5/75 | 5.6 |
| Modified PAGE-B | ||||||
| Low (≤8) | 0/139 | 0.0 | 0/107 | 0.0 | 0/32 | 0.0 |
| Intermediate (9–12) | 8/670 | 0.9 | 4/542 | 0.4 | 4/128 | 3.1 |
| High (≥13) | 15/391 | 2.8 | 8/335 | 1.9 | 7/56 | 7.4 |
| aMAP | ||||||
| Low (<50) | 0/300 | 0.0 | 0/244 | 0.0 | 0/56 | 0.0 |
| Intermediate (50–60) | 14/674 | 2.4 | 8/552 | 1.8 | 6/122 | 5.7 |
| High (>60) | 9/226 | 6.3 | 4/188 | 2.5 | 5/38 | 26.7 |
aMAP, age-male-ALBI-platelets; AVT, antiviral therapy; CU-HCC, Chinese University-HCC; GAG-HCC, guide with age, gender, HBV DNA, core promoter mutations and cirrhosis; HCC, hepatocellular carcinoma; PAGE-B, platelets, age, gender hepatitis B; REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B.